Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.78 (market cap $1.46B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 87.8× YieldMax NVDA Option Income Strategy ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax NVDA Option Income Strategy ETF for 43 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| NVDY | VRTX | |
|---|---|---|
Market Cap | $1.46B | $128.16B |
Volume | 1,111,033 | 806,603 |
Sector | Income / Options Overlay | Health |
52-Week High | $17.21 | $557.96 |
52-Week Low | $11.58 | $407.37 |
Typical Hold Time | 43 Days | 120 Days |
Enterprise Value | — | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY trades at $13.01, down 0.31% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF generates weekly dividends, averaging around $0.10 per share recently, reflecting its income-focused strategy tied to NVIDIA's stock volatility. However, key valuation ratios like P/E and P/S are unavailable, limiting fundamental clarity.
The outlook is mixed: strong dividend yields appeal to income seekers, but structural caps on upside participation and potential NAV erosion pose long-term risks. Analyst sentiment has shifted to hold due to declining volatility in NVIDIA, suggesting cautious optimism for income but limited growth potential.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
